BridgeBio Pharma (BBIO) News Today $23.04 +0.50 (+2.22%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period BridgeBio Pharma’s Promising Developments and Undervalued Market Position: A Buy Rating AnalysisNovember 20 at 5:14 AM | markets.businessinsider.comBridgeBio Pharma (BBIO) Gets a Buy from ScotiabankNovember 20 at 5:14 AM | markets.businessinsider.comEquities Analysts Offer Predictions for BBIO FY2024 EarningsNovember 20 at 3:14 AM | americanbankingnews.comBridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM MarketNovember 19 at 2:44 PM | benzinga.comBridgeBio reports open-label extension data on acoramidis in ATTR-CMNovember 19 at 7:56 AM | markets.businessinsider.comThe Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell DramaticallyNovember 19 at 7:56 AM | finance.yahoo.comFirst Turn Management LLC Makes New $10.18 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)First Turn Management LLC acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 399,781 shares of the company's stock, vaNovember 19 at 6:08 AM | marketbeat.comRoyce & Associates LP Takes $3.11 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Royce & Associates LP bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 121,955 shares of the company's stock, valued at approximately $3November 19 at 4:34 AM | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $45.00 at ScotiabankNovember 19 at 1:33 AM | americanbankingnews.comOpen-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 MonthsNovember 18 at 11:15 AM | globenewswire.comBridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with AchondroplasiaNovember 18 at 5:30 AM | globenewswire.comFY2024 EPS Forecast for BridgeBio Pharma Reduced by AnalystBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2024 earnings estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now forecasts tNovember 18 at 2:45 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has earned an average rating of "Moderate Buy" from the fifteen analysts that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. TheNovember 17, 2024 | marketbeat.comBridgeBio price target raised to $45 from $44 at ScotiabankNovember 16, 2024 | markets.businessinsider.comBridgeBio Pharma’s Strategic Advancements and Promising Prospects Drive Buy RecommendationNovember 15, 2024 | markets.businessinsider.comScotiabank Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock PriceScotiabank raised their price target on BridgeBio Pharma from $44.00 to $45.00 and gave the company a "sector outperform" rating in a report on Friday.November 15, 2024 | marketbeat.comLeerink Partnrs Has Negative Outlook of BBIO FY2024 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Research analysts at Leerink Partnrs reduced their FY2024 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report released on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now expects that the company will poNovember 15, 2024 | marketbeat.comBridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With CaveatsNovember 14, 2024 | seekingalpha.comLeerink Partnrs Has Negative Outlook of BBIO FY2028 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for BridgeBio Pharma in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now forecasts thaNovember 14, 2024 | marketbeat.comBridgeBio Pharma Reports Quarterly Loss Amid RestructuringNovember 14, 2024 | markets.businessinsider.comEvercore ISI Remains a Buy on BridgeBio Pharma (BBIO)November 14, 2024 | markets.businessinsider.comBridgeBio Pharma (BBIO) Gets a Hold from OppenheimerNovember 14, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)November 13, 2024 | markets.businessinsider.comWCM Investment Management LLC Purchases 86,987 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)WCM Investment Management LLC lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 49.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 263,679 shares of the company's stock after acquiring an additional 86,987November 12, 2024 | marketbeat.comBridgeBio Dives on Revealing Case StudyNovember 5, 2024 | baystreet.caBridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio ManagementNovember 5, 2024 | finance.yahoo.comBridgeBio announces publication on impact of biomedical innovationNovember 5, 2024 | markets.businessinsider.comBridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio ManagementNovember 5, 2024 | globenewswire.comEmerald Advisers LLC Has $28.10 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Emerald Advisers LLC lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 65.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,103,508 shares of the company's stock after buying an adNovember 3, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 8.3% - Here's WhyBridgeBio Pharma (NASDAQ:BBIO) Trading 8.3% Higher - Here's WhyNovember 1, 2024 | marketbeat.comBridgeBio shares preliminary data from CANaspire Phase 1/2 trial of BBP-812October 25, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for BridgeBio Pharma (NASDAQ:BBIO)HC Wainwright reissued a "buy" rating and set a $43.00 target price on shares of BridgeBio Pharma in a research note on Friday.October 25, 2024 | marketbeat.comBridgeBio Pharma Presents Positive Data From CANaspire Phase 1/2 Study In Canavan DiseaseOctober 24, 2024 | markets.businessinsider.comBridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024October 24, 2024 | globenewswire.comInvestors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three yearsOctober 24, 2024 | finance.yahoo.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and thirteen have assigned a buOctober 23, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) PT Lowered to $46.00 at Leerink PartnersLeerink Partners decreased their target price on shares of BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating for the company in a report on Thursday.October 17, 2024 | marketbeat.comEquities Analysts Offer Predictions for BridgeBio Pharma, Inc.'s Q3 2024 Earnings (NASDAQ:BBIO)BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Leerink Partnrs decreased their Q3 2024 earnings per share (EPS) estimates for BridgeBio Pharma in a note issued to investors on Monday, October 14th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will posOctober 17, 2024 | marketbeat.comBridgeBio Pharma Receives ‘Buy’ Rating Amid Positive Regulatory Outlook for AcoramidisOctober 17, 2024 | markets.businessinsider.comBridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at ScotiabankScotiabank initiated coverage on shares of BridgeBio Pharma in a research report on Wednesday. They set a "sector outperform" rating on the stock.October 16, 2024 | marketbeat.comOptimistic Patent Litigation Outlook Strengthens Buy Rating for BridgeBio PharmaOctober 11, 2024 | markets.businessinsider.comBridgeBio Pharma (NASDAQ:BBIO) Shares Up 4.7% - Should You Buy?BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 4.7% - Here's What HappenedOctober 10, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Down 4.6% - Here's What HappenedBridgeBio Pharma (NASDAQ:BBIO) Shares Down 4.6% - Time to Sell?October 9, 2024 | marketbeat.comMarshall Wace LLP Acquires Shares of 30,849 BridgeBio Pharma, Inc. (NASDAQ:BBIO)Marshall Wace LLP bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 30,849 shares of the company's stock, valued at approximately $781,000. Several other large investorsOctober 9, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Stock, Short Interest ReportOctober 7, 2024 | benzinga.com3 Top Stocks That Could Still Rocket Higher in 2024October 4, 2024 | fool.comAlgert Global LLC Has $1.42 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Algert Global LLC trimmed its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 37.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,848 shares of the company's stock afterOctober 4, 2024 | marketbeat.comOppenheimer Initiates Coverage of BridgeBio Pharma (BBIO) with Perform RecommendationOctober 4, 2024 | msn.comBridgeBio granted Perform rating at Oppenheimer on market challengesOctober 3, 2024 | seekingalpha.comBridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific SessionsOctober 3, 2024 | globenewswire.com Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼0.170.45▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼327▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perrigo News Amicus Therapeutics News Arrowhead Pharmaceuticals News Schrödinger News Allakos News Viatris News Summit Therapeutics News Moderna News Genmab A/S News Dr. Reddy's Laboratories News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.